Loading clinical trials...
Loading clinical trials...
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Adults With Non-Transfusion Dependent Beta (β)-Thalassemia (The BEYOND™ Study)
Conditions
Interventions
Luspatercept
Placebo
+1 more
Locations
16
United States
Children's Hospital of Los Angeles
Los Angeles, California, United States
Local Institution - 501
Los Angeles, California, United States
Children's Hospital and Research Center at Oakland
Oakland, California, United States
Local Institution - 503
Chicago, Illinois, United States
Local Institution - 102
Athens, Greece
Local Institution - 101
Athens, Greece
Start Date
February 5, 2018
Primary Completion Date
November 28, 2022
Completion Date
November 28, 2022
Last Updated
December 20, 2023
NCT06647979
NCT07292259
NCT03653338
NCT07112703
NCT06490627
NCT06772766
Lead Sponsor
Celgene
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions